About CLL
Safety Information
 

Some Treatment Options for CLL

You may just be starting treatment for your CLL. Or you may need treatment again because the disease has advanced (relapse).

There are many treatment options for chronic lymphocytic leukemia (CLL). Some goals of treatment are to:

  • Relieve symptoms
  • Keep the disease from advancing
  • Get the disease into partial or complete remission
 
 

Keep in mind: Remission can be partial or complete. Partial remission means the cancer is significantly improved, but evidence of the cancer remains. Complete remission means all evidence of the cancer is gone for a period of time.

Some common treatment options include:

  • Watch-and-wait—An option that involves watching for symptoms of CLL and not starting treatment unless needed. Some people with CLL never need treatment
    Learn more about watch-and-wait
  • Chemotherapy—Drugs used to attack cells that are fast growing. This includes cancer cells and different types of healthy cells throughout the body
    Learn more about chemotherapy and CLL
  • Targeted therapy—A type of treatment that attacks a specific type of cell. This includes the group of healthy cells from which cancer cells derive
    Learn more about targeted therapy and CLL

The right treatment for you depends on a number of factors. These include:

  • The stage of CLL—where the CLL is in your body
  • Your personal characteristics—such as age and overall health

Treatments may vary from patient to patient. And when you’ve been treated before, remember that your response may not be as good the second time around. Still, it is important to understand what options are available and to discuss your treatment goals with your doctor.

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.

Next Section Watch-and-Wait

Indications

RITUXAN® (Rituximab) is indicated in combination with fludarabine and cyclophosphamide (FC chemotherapy) for the treatment of patients with:

  • Previously untreated CD20-positive CLL
  • Previously treated CD20-positive CLL

People with serious infections should not receive RITUXAN.

Safety Information

  • RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in clinical trials of patients with CLL were infusion reactions and low white blood cells, which can increase the risk of infections. Before starting treatment with RITUXAN it is important for you to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide, in PDF format.